Research Article

Association between the estrogen receptor α gene polymorphisms rs2234693 and rs9340799 and severe and mild pre-eclampsia: a meta-analysis

Ge Zhao1, Yunfei Cai2, Jing Liu1 and Tao Meng1

1Department of Obstetrics, The First Hospital of China Medical University, No. 155 Nanjing Bei Street, Heping District, Shenyang, Liaoning Province, P.R. China 110001; 2Department of Dermatology, The First Hospital of China Medical University, No. 155 Nanjing Bei Street, Heping District, Shenyang, Liaoning Province, P.R. China 110001

Correspondence: Tao Meng (mengtaocmu1@163.com)

This meta-analysis was performed in order to determine the associations between the estrogen receptor α (ESR1) gene PvuII site (-397T/C, rs2234693) and XbaI site (-351A/G, rs9340799) polymorphisms with severe and mild pre-eclampsia. Eligible studies were identified by searching PubMed, Medline, Embase, China National Knowledge Infrastructure (CNKI), and WanFang databases until May 2018. The pooled odds ratio (OR) and 95% confidence interval (CI) were used to calculate the associations. Six articles (consisting of seven studies; one article was considered as two separate studies with two different sub-populations) investigated the ESR1 gene PvuII -397T/C and XbaI -351A/G polymorphisms in severe and mild pre-eclampsia patients and included controls. The pooled results indicated an increased risk of severe pre-eclampsia for the XbaI -351A/G polymorphism (OR = 1.67, 95% CI = 1.10–2.25, P = 0.017 for GG compared with AA+GA; OR = 1.81, 95% CI = 1.17–2.82, P = 0.008 for GG compared with GA). The GG genotype of the ESR1 XbaI polymorphism could be a genetic risk factor for severe pre-eclampsia susceptibility. However, the ESR1 gene PvuII -397T/C polymorphism was not significantly associated with the risk of severe pre-eclampsia, and there was no association between mild pre-eclampsia and the ESR1 gene PvuII -397T/C and XbaI -351A/G polymorphisms separately. The current meta-analysis indicates that the ESR1 XbaI genetic polymorphism may be associated with severe pre-eclampsia. However, there was no association of the ESR1 gene PvuII and XbaI polymorphisms with the risk of mild pre-eclampsia. Owing to the low statistical power, the results may not be sufficiently robust and this conclusion should be interpreted cautiously, which highlights the requirement for large-scale and high-quality studies in this field.

Introduction

Pre-eclampsia is a major leading cause of maternal mortality worldwide (2–5%), affecting women after 20 weeks of pregnancy, and is characterized by increased systemic vascular resistance, decreased blood volume, vascular endothelial cell destruction, and renal hemodynamic abnormalities [1]. Annually, approximately 40000 maternity patients could die due to pre-eclampsia and eclampsia resulting from a shallow implanted placenta, leading to severe immune reaction involved with inflammatory mediators of the placenta, and acting on the vascular endothelium [1]. Pre-eclampsia is the result of genetic components interacting closely with environmental influences; however, the etiology of pre-eclampsia remains to be elucidated [2].

The estrogen receptor α (ESR1) gene is located on the long arm of chromosome 6 (6q25.1) and contains eight exons [3]. ESR1 is a ligand-activated transcription factor that can be activated by growth factors in the
absence of estrogen [4]. The N-terminus of ESR1 plays a critical role in activating ESR1-reliant genes, and any mutations in this location have been associated with high blood pressure [3,5–7]. Several ESR1 gene polymorphisms have associations with severe and mild pre-eclampsia, and two of the most investigated polymorphisms in intron 1 are ESR1 PvuII -397T/C (rs2234693) and XbaI -351A/G (rs9340799).

The association between ESR1 PvuII -397T/C (rs2234693) and XbaI -351A/G (rs9340799) polymorphisms with the risk of severe and mild pre-eclampsia was found to be inconsistent. Therefore, a meta-analysis of six articles (seven studies) was performed to investigate the association between ESR1 polymorphisms and the risk of severe and mild pre-eclampsia.

Methods

Literature search

Literature published until May 2018 was retrieved from the PubMed, Medline, Embase, China National Knowledge Infrastructure (CNKI), and WanFang databases, both English and Chinese language articles were included. The search strategies contained combinations of the following terms: ('estradiol receptor α' or 'ER alpha' or 'estrogen receptor 1' or 'ESR1'), ('polymorphism' or 'variant' or 'mutation'), and ('pre-eclampsia' or 'severe pre-eclampsia' or 'mild pre-eclampsia'). Reference lists were also retrieved and manually searched to identify additional potential studies.

Inclusion and exclusion criteria

Inclusion criteria

Included studies met the following criteria: (i) assessing the association of ESR1 -397T/C PvuII (rs2234693) or -351A/G XbaI (rs9340799) polymorphisms with the risk of pre-eclampsia, (ii) sufficient data to calculate the odds ratio (OR) with 95% confidence interval (CI), and (iii) case–control study.

Exclusion criteria

Studies were excluded based on the following criteria: (i) overlapping data, (ii) reviews, letters, editorial articles, or meta-analysis, and (iii) incomplete data regarding genotype distribution in cases and controls.

Data extraction

Two researchers independently extracted data from each included study and any discrepancies were resolved through discussion. The following information was extracted from each study: first author, year of publication, disease categories, age of controls, genotyping method, sample size of cases and controls, genotype distribution in cases and controls.

Quality evaluation of the included studies

The methodological quality of included studies was independently evaluated by two researchers according to the Newcastle–Ottawa Scale (NOS) [8]. The NOS quality score ranges from 0 to 9 stars, which is categorized based on three criteria: selection, comparability, and exposure assessment. Scores equal to or greater than 7 indicated high methodological quality; a score below 7 indicated the study should be considered ‘low quality’. Discrepancies were resolved through discussion.

Statistical analysis

The Hardy–Weinberg equilibrium (HWE) was calculated in the control groups using the chi-squared test, with \( P < 0.05 \) considered as a deviation. Dichotomous data are presented as OR with 95% CI. Heterogeneity was assessed using the \( Q \) test and quantified by the \( I^2 \) test. If there was no heterogeneity (\( P > 0.1 \) or \( I^2 < 50\% \)), a fixed-effects model (Mantel–Haenszel method) was used to estimate the pooled OR; otherwise, a random-effects model (Mantel–Haenszel method) was utilized. For the PvuII -397T/C polymorphism, the allele (C compared with T), dominant (CC+CT compared with TT), recessive (CC compared with TT+CT), homozygous (CC compared with TT), and heterozygous model (CC compared with CT) were evaluated. For the XbaI -351A/G polymorphism, the allele (G compared with A), dominant (GG+GA compared with AA), recessive (GG compared with AG+AA), homozygous (GG compared with AA), and heterozygous model (GG compared with GA) were evaluated. The \( Z \) test was conducted to estimate the statistical significance of summary results, with \( P < 0.05 \) indicating statistical significance. Sensitivity analysis was conducted to assess the stability and quality of the pooled results. The Egger’s test was conducted to evaluate publication bias and in order to assess the potential impact of publication bias on the OR estimate.
we estimated an OR adjusted for publication bias using the trim-and-fill method, which imputes potentially missing studies to achieve symmetry in the funnel plot [9]; \(P<0.05\) indicated statistical significance. All statistical analysis was performed using Stata 12.0 software (Stata Corporation, College Station, TX, U.S.A.). Statistical power analysis was performed using Power and Precision V4 software (free download available at http://www.power-analysis.com/) to verify whether the included studies and meta-analysis could offer adequate power (≥80%).

Results

Characteristics of the included studies

The selection process of eligible articles is shown in Figure 1. The search strategy identified 65 potentially relevant articles. Based on the inclusion and exclusion criteria, six articles [10–15] (consisting of seven studies, with one article considered as two separate studies with two different subpopulations) were included in the meta-analysis. Of these seven studies: seven studies assessed the association between the ESR1 -397T/C PvuII polymorphism and severe pre-eclampsia susceptibility, five studies assessed the ESR1 -397T/C PvuII polymorphism and mild pre-eclampsia susceptibility, four studies assessed the ESR1 -351A/G XbaI polymorphism and severe pre-eclampsia susceptibility, and three studies assessed the ESR1 -351A/G XbaI polymorphism and mild pre-eclampsia susceptibility. The corresponding characteristics are shown in Table 1.

Meta-analysis of the ESR1 -397T/C PvuII polymorphism and severe pre-eclampsia

The seven selected studies [10–15], which included 479 cases and 952 controls, were used to determine the association between the ESR1 -397T/C PvuII polymorphism and severe pre-eclampsia susceptibility. A summary of meta-analysis for the association between the ESR1 -397T/C PvuII polymorphism and severe pre-eclampsia is shown in Table 2. There was no association between the -397T/C polymorphism in the ESR1 gene and susceptibility to severe pre-eclampsia.
Table 1 Main characteristics of all studies included in the meta-analysis

| Author          | Year | Country/ethnicity | Disease categories | Age (controls) | Genotyping method | Sample size (case/control) | Cases |
|-----------------|------|-------------------|-------------------|----------------|-------------------|-----------------------------|-------|
| -397T/C; PvuII restriction site (rs2234693) |
| Severe pre-eclampsia |
| Salimi S.       | 2017 | Iran              | Severe            | 26.5 ± 6.3     | PCR-RFLP          | 192/186                     | 9     |
| El-Beshbishy H.A.| 2015 | Saudi             | NA                | 24 ± 2.9       | PCR-RFLP          | 97/94                       | 21    |
| Groten T.       | 2014 | Caucasian         | Severe            | NA             | PCR               | 27/175                      | 5     |
| Groten T.       | 2014 | African           | Severe            | NA             | PCR               | 16/134                      | 3     |
| Zhang J.        | 2009 | Chinese Han       | Severe            | 28.71 ± 3.60   | PCR               | 140/236                     | 48    |
|                 |      |                   |                   |                |                   |                             |       |
| Mild pre-eclampsia |
| Molvarec A.     | 2006 | Caucasian         | Severe            | 28 (25–31)     | PCR               | 119/103                     | 26    |
| Tempfer C.B.    | 2004 | Caucasian         | Severe            | 29 (21–43)     | PCR               | 24/24                       | 4     |
| -351A/G; XbaI restriction site (rs9340799) |
| Severe pre-eclampsia |
| Salimi S.       | 2017 | Iran              | Severe            | 26.5 ± 6.3     | PCR-RFLP          | 142/186                     | 28    |
| El-Beshbishy H.A.| 2015 | Saudi             | NA                | 24 ± 2.9       | PCR-RFLP          | 97/94                       | 21    |
| Molvarec A.     | 2006 | Caucasian         | Severe            | 28 (25–31)     | PCR               | 119/103                     | 19    |
| Zhang J.        | 2009 | Chinese Han       | Severe            | 28.71 ± 3.60   | PCR               | 140/236                     | 7     |
| Mild pre-eclampsia |
| Salimi S.       | 2017 | Iran              | Mild              | 26.5 ± 6.3     | PCR-RFLP          | 142/186                     | 13    |
| El-Beshbishy H.A.| 2015 | Saudi             | NA                | 24 ± 2.9       | PCR-RFLP          | 97/94                       | 13    |

Abbreviations: NA, not available; RFLP-PCR, restriction fragment length polymorphism PCR.
Table 2: Meta-analysis of associations between the ESR1 gene polymorphism and severe and mild preeclampsia

| Polymorphism | Comparison | No. of Studies | Test of associations | Test of heterogeneity | Model | Egger’s test | Sensitivity analysis |
|--------------|------------|----------------|----------------------|-----------------------|-------|-------------|---------------------|
|              |            |                | OR (95%CI) P value | I² (%) I² P value    |       |             | OR (95%CI) P value  |
| -397 T/C PvuII (rs2234693) | Severe preeclampsia | C vs. T 7 | 1.02(0.87,1.2) 0.796 | 0 0.892 F | 0.880 | 0.99(0.83,1.2) 0.960 |
|              |            | CC+CT vs. TT 7 | 1.05(0.81,1.3) 0.713 | 0 0.890 F | 0.520 | 0.99(0.74,1.3) 0.917 |
|              |            | CC vs. TT 7 | 1.01(0.76,1.3) 0.963 | 0 0.935 F | 0.438 | 1.01(0.74,1.35) 0.982 |
|              |            | CC vs. CT 7 | 1.04(0.74,1.4) 0.828 | 0 0.900 F | 0.874 | 0.99(0.68,1.43) 0.953 |
|              |            | Mild preeclampsia | C vs. T 5 | 1.02(0.86,1.2) 0.783 | 0 0.426 F | 0.919 | 0.99(0.83,1.2) 0.967 |
|              |            | CC+CT vs. TT 5 | 1.08(0.83,1.4) 0.562 | 0 0.627 F | 0.996 | 1.02(0.75,1.38) 0.907 |
|              |            | CC vs. TT 5 | 0.98(0.74,1.3) 0.884 | 7 0.367 F | 0.696 | 0.97(0.71,1.33) 0.850 |
| -351 A/G XbaI (rs9340799) | Severe preeclampsia | G vs. A 4 | 1.1(0.91,1.3) 0.331 | 0 0.390 F | 0.636 | 1.14(0.91,1.43) 0.255 |
|              |            | GG+GA vs. AA 4 | 0.97(0.74,1.2) 0.846 | 5 0.407 F | 0.205 | 1.01(0.74,1.36) 0.979 |
|              |            | GG vs. AA 4 | 1.67(1,1,2) 0.55 0.017 | 30.6 0.228 F | 0.808 | 1.81(1,1,2,1,5) 0.016 |
|              |            | GG vs. GA 4 | 1.43(0.9,2,2) 0.125 | 14.2 0.321 F | 0.925 | 1.54(0.9,1,2,8) 0.106 |
|              |            | Mild preeclampsia | G vs. A 3 | 1.03(0.83,1.2) 0.784 | 0 0.563 F | 0.337 | 1.04(0.81,1.35) 0.747 |
|              |            | GG+GA vs. AA 3 | 0.9(0.67,1.2) 0.494 | 35.1 0.214 F | 0.483 | 0.91(0.65,1.3) 0.613 |
|              |            | GG vs. AA 3 | 1.13(0.67,1.9) 0.647 | 0 0.545 F | 0.212 | 1.04(0.54,2,0) 0.897 |
|              |            | GG vs. GA 3 | 1.12(0.64,1,9) 0.697 | 0 0.858 F | 0.047 | 1.11(0.56,2,23) 0.759 |

Abbreviations: OR: odds ratio; 95% CI: 95% confidence interval; F: fixed effects model; R: random effects model; No.: number.

Meta-analysis of the ESR1 -397T/C PvuII polymorphism and mild pre-eclampsia

In total, five studies [10,11,14,15], containing 432 cases and 825 controls, identified an association between the ESR1 -397T/C PvuII polymorphism and mild pre-eclampsia susceptibility. A summary of meta-analysis for the association between the ESR1 -397T/C PvuII polymorphism and mild pre-eclampsia is shown in Table 2. We did not find a significant association between the ESR1 -397T/C PvuII polymorphism and mild pre-eclampsia in allele frequency and genotype distribution between cases and controls.

Meta-analysis of the ESR1 -351A/G XbaI polymorphism and severe pre-eclampsia

In total, we identified four studies [10–12,14], containing 406 cases and 619 controls, that were used to assess the effect of the ESR1 -351A/G XbaI polymorphism on the susceptibility to severe pre-eclampsia. A summary of meta-analysis for the association between the ESR1 -351A/G XbaI polymorphism and severe pre-eclampsia is shown in Table 2. There were significant associations for both GG compared with AA+GA (OR = 1.67, 95% CI = 1.10–2.55, P = 0.017) (Figure 2) and GG compared with GA genotype (OR = 1.81, 95% CI = 1.17–2.82, P = 0.008) (Figure 3); other comparisons failed to identify any significant association. This indicates that the GG genotype of the ESR1 XbaI polymorphism could be a genetic risk factor for severe pre-eclampsia susceptibility.
Meta-analysis of the ESR1 -351A/G Xbal polymorphism and mild pre-eclampsia

In total, we identified three studies [10,11,14], containing 303 cases and 616 controls, that were used to assess the effect of the ESR1 -351A/G Xbal polymorphism on mild pre-eclampsia susceptibility. A summary of meta-analysis for the association between the ESR1 -351A/G Xbal polymorphism and mild pre-eclampsia is shown in Table 2. We did not find a significant association between the ESR1 -351A/G Xbal polymorphism and mild pre-eclampsia in allele frequency and genotype distribution between cases and controls.

Sensitivity analysis

In one study, it is unclear whether the pre-eclampsia patients were mildly or severely affected [14], so we performed sensitivity analysis excluding this study to check the robustness of our result. This study was omitted to evaluate the influence on the combined OR. The results show that the corresponding pooled OR was not qualitatively altered (Table 2), indicating that the pooled analysis was stable and reliable. Moreover, the genotype distribution of the controls in two studies [12,14] significantly deviated from HWE in this meta-analysis. We also performed sensitivity analysis...
Table 3 Statistical power analysis of eligible studies and meta-analyses of ESR1 -351 A/G XbaI polymorphism and severe and mild pre-eclampsia susceptibility

| Study                  | Comparison | Salimi S. | El-Beshbishy H.A. | Zhang J. | Molvarec A. | Overall |
|------------------------|------------|-----------|-------------------|----------|-------------|---------|
| -351 A/G and severe pre-eclampsia | G vs. A    | 28%       | 5%                | 16%      | 10%         | 46%     |
|                        | GG+GA vs. AA | 5%       | 7%                | 16%      | 26%         | 10%     |
|                        | GG vs. AA+GA | 83%      | 10%               | 16%      | 7%          | 72%     |
|                        | GG vs. AA  | 56%       | 5%                | 15%      | 6%          | 63%     |
|                        | GG vs. GA  | 89%       | 9%                | 9%       | 12%         | 57%     |
| -351 A/G and mild pre-eclampsia | G vs. A    | 6%        | 22%               | 5%       | 25%         | 6%      |
|                        | GG+GA vs. AA | 12%      | 42%               | 7%       | 14%         | 12%     |
|                        | GG vs. AA+GA | 6%       | 22%               | 10%      | 26%         | 6%      |
|                        | GG vs. AA  | 5%        | 10%               | 5%       | 45%         | 5%      |
|                        | GG vs. GA  | 7%        | 26%               | 9%       | 39%         | 7%      |

excluding the HWE-violating studies to check the robustness of our results. Our findings show that before excluding the two studies that deviated from HWE [12,14], the GG genotype increased the risk of severe pre-eclampsia. However, after excluding the two studies, the results were materially altered and the effect of the GG genotype on the risk of severe pre-eclampsia was not significant.

**Publication bias**

To identify publication bias, the Egger’s test was performed on each model of the ESR1 gene PvuII and XbaI polymorphisms. The results suggest that there was evidence for publication bias in the GG compared with AA model of the -351A/G XbaI (rs9340799) polymorphism and mild pre-eclampsia, as indicated by Egger’s asymmetry test ($P=0.047$) (Table 2). Using the trim-and-fill method, four additional artificial studies were included in the meta-analysis to generate a symmetric funnel plot. This correction for publication bias yielded an OR of 1.01 (95% CI = 0.63–1.59; $P=0.921$), however, the presence of publication bias did not influence the OR estimate and overall result (OR = 1.12, 95% CI = 0.64–1.97, $P=0.697$). The subsequent trim-and-fill method showed that publication bias had little impact on the stability of the results.

**Statistical power analysis**

We adopted the statistical power analysis to reassess the available data when an $\alpha$ of 0.05 and $\beta$ of 0.2 were assigned. The power of each eligible study of the association between the ESR1 -351A/G XbaI polymorphism and severe and mild pre-eclampsia susceptibility ranged from 5% to 89%, 5% to 45%, respectively. In the meta-analysis of the association between the ESR1 -351A/G XbaI polymorphism and severe pre-eclampsia susceptibility, the power analysis suggests that a power of 57% was required to detect a pooled OR for the GG compared with GA model, and 72% for a pooled OR for the GG compared with AA+GA model. The specific power values are summarized in Table 3.

**Discussion**

The familial nature of pre-eclampsia has been known for a number of years, and the identification of novel susceptibility genes is one of many strategies aimed at fully elucidating the underlying biological pathogenetic mechanisms [16]. The gene encoding ESR1 is located on the 6q25.1 chromosome and includes eight exons and seven introns, encoding a protein of 595 amino acids with a molecular size of 66 kDa [17]. A multitude of variations in the ESR1 gene have been identified, which may influence ESR1 protein structure or activity. The most common polymorphisms are rs2234693 (T>C: PvuII) and rs9340799 (A>G: XbaI), which are located in intron 1 of the ESR1 gene. The PvuII, T397C polymorphism occurs due to T>C transition in intron 1; while the XbaI, G351A polymorphism is a G>A transition located 50 bp from the PvuII polymorphic site [18]. For the ESR1 PvuII gene polymorphism, it has been demonstrated that the C allele forms part of a functional binding site for the B-myb transcription factor and it acts as an intragenic enhancer [19]. As estrogen is believed to be involved in up-regulating the transcription of myb [20], the presence of a PvuII site corresponding to the T allele may lead to decreased ESR1 expression, and therefore the effects of estrogen mediated by ESR1 may be reduced, resulting in a relative estrogen deficit. The XbaI polymorphism might also have functional importance that remains unclear [12]. Interpretation of genetic studies involving pre-eclampsia...
is hindered by differences in definition of the disease, size of study population, diverse ethnicity between studies, and ethnic mixing within studies [16]. Furthermore, environmental factors may also affect an individual's susceptibility to the development of pre-eclampsia [11]. Further large-scale studies with different ethnicities are required to gain insight and explore the mechanism of ESR1 gene polymorphism in pre-eclampsia.

Our meta-analysis suggests that the GG genotype of the ESR1 XbaI polymorphism could be a genetic risk factor for severe pre-eclampsia susceptibility. As HWE is a surrogate to assess study quality, the chi-squared test was conducted to check whether genotype distributions in controls conformed to the HWE rule. However, the genotype distribution of the controls in two studies [12,14] significantly deviated from HWE in this meta-analysis. Sensitivity analysis was performed by excluding the HWE-violating studies to check the robustness of our results. Our findings show that before excluding the two studies that deviated from HWE [12,14], the GG genotype increased the risk of severe pre-eclampsia. However, upon excluding the two studies, the results were materially altered and the effect of the GG genotype on the risk of severe pre-eclampsia was not significant. The deviation from HWE could be due to population stratification, non-random mating, genotyping error, genetic drifting, chance, and selection bias. In the case of meta-analysis, it is unclear which factor is responsible due to insufficient data. Sensitivity analysis including and excluding the HWE-violating studies was recommended [21]; consequently, the results of this meta-analysis should be interpreted with caution. Minelli et al. [22] found no evidence of a strong association between departures from HWE and estimating the genetic effect.

The meta-analysis was a powerful way to effectively increase the sample size to provide a more valid pooled estimate. However, the highest statistical power of the pooled result on the overall meta-analysis of the ESR1 -351A/G XbaI polymorphism and severe and mild pre-eclampsia susceptibility was found to be 72 and 12%, respectively, which are less than 80%, i.e. the powers of our findings were unsatisfactory. Owing to the low statistical power, the results may not be sufficiently robust, and any conclusions should be interpreted cautiously. Statistical power depends upon the population effect size, number of studies, and average sample size. As the pooled sample size (only three or four studies) is not large enough, the statistical power to estimate the effect of this locus may be limited, and thus further large-scale and high-quality studies are necessary to validate our findings.

There was evidence of publication bias in the GG compared with AA model of the -351A/G XbaI (rs9340799) polymorphism and mild pre-eclampsia, however, this did not impact the combined OR estimate (Duval and Tweedie's trim-and-fill adjusted OR). The subsequent trim-and-fill method showed that publication bias had little influence on the stability of the results. Publication bias of our meta-analysis was attributed to the limited availability of published results, as the number of publications included in our meta-analysis was relatively small.

The present meta-analysis has some limitations that should be discussed. First, only four studies assessed the ESR1 -351A/G XbaI polymorphism and severe pre-eclampsia susceptibility, and three studies assessed the ESR1 -351A/G XbaI polymorphism and mild pre-eclampsia susceptibility. Hence, the limited study number and small sample size may not offer sufficient statistical power to investigate the association between the ESR1 polymorphisms and the risk of severe or mild pre-eclampsia. As the statistical power may be limited, more large-scale and high-quality studies will be required to evaluate the risk of pre-eclampsia in different ethnic groups and validate the meta-analysis. Second, all the included studies are case–control and all had the limitation of being observational studies, including selection bias and unmeasured confounders. Third, our meta-analysis did not investigate the genetic haplotypes of severe or mild pre-eclampsia, and only single locus SNP -397T/C PvuII or -351A/G XbaI in the ESR1 gene were analyzed in the present study. It therefore remains unclear whether additional genetic variants contribute to this gene; investigating haplotypes reveal more information regarding the genetic causes of diseases than genotypes and hence would be more influential than single SNPs. Fourth, including only English and Chinese articles may produce publication bias and more eligible studies could be captured if the search was extended. The selection bias caused by language restriction may reduce the robustness of our meta-analysis [23,24]. Finally, environmental factors may affect the development of pre-eclampsia; however, we did not consider environmental factors, such as living habits and diets, or potential gene–environment interactions that might lead to bias in the results.

**Conclusion**

In conclusion, our meta-analysis suggests that the GG genotype of the ESR1 XbaI polymorphism may be a genetic risk factor for severe pre-eclampsia susceptibility. However, there is no association between the ESR1 gene PvuII and XbaI promoter polymorphism and the risk of mild pre-eclampsia. Due to the limitations mentioned above, well-designed and larger scale studies are necessary to validate our results, and such investigations may explore the roles of the ESR1 XbaI gene polymorphism in the pathogenesis of severe pre-eclampsia.
Acknowledgements
We thank all the participants in the present study.

Author contribution
G.Z., Y.C. and T.M. conceived and designed the meta-analysis. G.Z., Y.C. and J.L. performed the literature search. Y.C. analyzed the data. G.Z. and J.L. wrote the paper.

Funding
The authors declare that there are no sources of funding to be acknowledged.

Competing interests
The authors declare that there are no competing interests associated with the manuscript.

Disclosure statement
This article has not been published elsewhere in whole or in part. All authors have read and approved the content and agree to submit for consideration for publication in the journal. There are no ethical/legal conflicts involved in the article.

Abbrevations
CI, confidence interval; CNKI, China National Knowledge Infrastructure; ESR1, estrogen receptor α; HWE, Hardy–Weinberg equilibrium; NOS, Newcastle–Ottawa Scale; OR, odds ratio.

References
1 Roberts, J.M. and Cooper, D.W. (2001) Pathogenesis and genetics of pre-eclampsia. Lancet 357, 53–56, https://doi.org/10.1016/S0140-6736(00)03577-7
2 Sibai, B., Dekker, G. and Kupferminc, M. (2005) Pre-eclampsia. Lancet 365, 785–799, https://doi.org/10.1016/S0140-6736(05)71003-5
3 Parker, M.G., Arbuckle, N., Dauvois, S., Danielian, P. and White, R. (1993) Structure and function of the estrogen receptor. Annu. N.Y. Acad. Sci. 684, 119–126, https://doi.org/10.1111/j.1749-6632.1993.tb22276.x
4 Mendelsohn, M.E. and Karas, R.H. (1999) The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. 340, 1801–1811, https://doi.org/10.1056/NEJM199906103402306
5 Lehrer, S., Rabin, J., Kalir, T. and Schachter, B.S. (1993) Estrogen receptor variant and hypertension in women. Hypertension 21, 439–441, https://doi.org/10.1161/HYP.21.4.439
6 Lehrer, S., Sanchez, M., Song, H.K. et al. (1990) Oestrogen receptor B-region polymorphism and spontaneous abortion in women with breast cancer. Lancet 335, 622–624, https://doi.org/10.1016/0140-6736(90)90410-7
7 Smith, E.P., Boyd, J., Frank, G.R. et al. (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331, 1056–1061, https://doi.org/10.1056/NEJM199410203311604
8 Stang, A. (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603–605, https://doi.org/10.1007/s10654-010-9491-z
9 Duval, S. and Tweedie, R. (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455–463, https://doi.org/10.1111/j.0006-341X.2000.00455.x
10 Salimi, S., Farajian-Mashhadi, F., Tabatabaee, E., Shahrakipour, M., Yaghmaei, M. and Mokhtari, M. (2017) Estrogen receptor alpha XbaI GG genotype was associated with severe preeclampsia. Clin. Exp. Hypertens. 39, 220–224, https://doi.org/10.1080/10641963.2016.1235182
11 Zhang, J., Bai, H., Liu, X. et al. (2009) Genotype distribution of estrogen receptor alpha polymorphisms in pregnant women from healthy and preeclampsia populations and its relation to blood pressure levels. Clin. Chem. Lab. Med. 47, 391–397, https://doi.org/10.1515/CCLM.2009.096
12 Molvarec, A., Ver, A., Fekete, A. et al. (2007) Association between estrogen receptor alpha (ESR1) gene polymorphisms and severe preeclampsia. Hypertens. Res. 30, 205–211, https://doi.org/10.1291/hypres.30.205
13 Tempfer, C.B., Jirecek, S., Riener, E.K. et al. (2004) Polymorphisms of thrombophilic and vasoactive genes and severe preeclampsia: a pilot study. J. Soc. Gynecol. Investig. 11, 227–231, https://doi.org/10.1016/j.jsgi.2003.12.002
14 El-Beshbishy, H.A., Tawfeek, M.A., Al-Azhary, N.M. et al. (2015) Estrogen receptor alpha (ESR1) gene polymorphisms in pre-eclamptic Saudi patients. Pakistan J. Med. Sci. 31, 880–885
15 Groten, T., Schleussner, E., Lehmann, T. et al. (2014) eNOSI4 and EPHX1 polymorphisms affect maternal susceptibility to preeclampsia: analysis of five polymorphisms predisposing to cardiovascular disease in 279 Caucasian and 241 African women. Arch. Gynecol. Obstet. 289, 581–593, https://doi.org/10.1007/s00404-013-2991-9
16 Mutze, S., Rudnik-Schoneborn, S., Zerres, K. and Rath, W. (2008) Genes and the preeclampsia syndrome. J. Perinat. Med. 36, 38–58, https://doi.org/10.1515/JPM.2008.004
17 Rigo, Jr, J., Boze, T., Derzszy, Z. et al. (2006) Family history of early-onset cardiovascular disorders is associated with a higher risk of severe preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 128, 148–151, https://doi.org/10.1016/j.ejogrb.2006.02.019
18 Roberts, J.M. and Gammill, H. (2005) Pre-eclampsia and cardiovascular disease in later life. Lancet 366, 961–962, https://doi.org/10.1016/S0140-6736(05)67349-7
19 Herrington, D.M., Howard, T.D., Brosnihan, K.B. et al. (2002) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105, 1879–1882, https://doi.org/10.1161/01.CIR.0000016173.98626.88
20 Swartz, C.D., Afshari, C.A., Yu, L., Hall, K.E. and Dixon, D. (2005) Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol. Hum. Reprod. 11, 441–450, https://doi.org/10.1093/molehr/gah174
21 Thakkinstian, A., McElduff, P., D’Este, C., Duffy, D. and Attia, J. (2005) A method for meta-analysis of molecular association studies. Stat. Med. 24, 1291–1306, https://doi.org/10.1002/sim.2010
22 Minelli, C., Thompson, J.R., Abrams, K.R., Thakkinstian, A. and Attia, J. (2008) How should we use information about HWE in the meta-analyses of genetic association studies? Int. J. Epidemiol. 37, 136–146, https://doi.org/10.1093/ije/dym234
23 Egger, M., Davey Smith, G., Schneider, M. and Minder, C. (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629–634, https://doi.org/10.1136/bmj.315.7109.629
24 Egger, M., Zellweger-Zahner, T., Schneider, M., Junker, C., Lengeler, C. and Antes, G. (1997) Language bias in randomised controlled trials published in English and German. Lancet 350, 326–329, https://doi.org/10.1016/S0140-6736(97)02419-7